The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.

开始日期2024-06-25

申办/合作机构

Novo Nordisk A/S

[+1]

NCT06263244

/ Not yet recruiting临床3期IIT

Specifying the Anti-inflammatory Effects of Ziltivekimab With Diverse Imaging Modalities and In-depth Cellular Phenotyping

The goal of this randomized, double blind, placebo controlled trial is to study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.

开始日期2024-04-01

申办/合作机构-

NCT06200207

/ Recruiting临床3期

Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.

开始日期2024-04-01

申办/合作机构

Novo Nordisk A/S

100 项与 Ziltivekimab 相关的临床结果

登录后查看更多信息

100 项与 Ziltivekimab 相关的转化医学

登录后查看更多信息

100 项与 Ziltivekimab 相关的专利（医药）

登录后查看更多信息

项与 Ziltivekimab 相关的文献（医药）

2024-12-01·Current Atherosclerosis Reports

“Anti-inflammatory Therapies in Atherosclerosis – Where are we going?”

Review

作者: Budoff, Matthew ; Iskander, Beshoy ; Kambalapalli, Soumya ; Roy, Sion K ; Krishnan, Srikanth ; Lakshmanan, Suvasini ; Ichikawa, Keishi ; Punnanithinont, Natdanai

PURPOSE OF REVIEW:

Inflammation has been commonly known for the past decade as a part of the pathophysiology of atherosclerosis, along with lipid accumulation. However, some patients with optimized lipid-lowering therapy still have elevated inflammatory biomarkers. Anti-inflammation therapies were developed to eradicate this residual risk. We summarized the primary inflammatory pathway and recent clinical trials in anti-inflammation therapies.

RECENT FINDINGS:

Colchicine Cardiovascular Outcomes Trial (COLCOT) and LoDoCo2 (Colchicine Reduces Risk of Major Cardiovascular Events in Chronic Coronary Disease) found that low-dose colchicine significantly reduced cardiovascular death, myocardial infarction (MI), ischemic stroke and coronary revascularization in patients with recent MI within 30 days and chronic coronary disease respectively. The US Food and Drug Administration approved low-dose colchicine in 2023 for patients with established atherosclerotic cardiovascular disease (ASCVD). However, its use was limited for chronic kidney disease (CKD) patients. Reduction in Inflammation in Patients with Advanced Chronic Renal Disease Utilizing Antibody Mediated Interleukin-6 Inhibition (RESCUE) was conducted using Ziltivekimab, an IL-6 ligand monoclonal antibody and found that it significantly reduced high-sensitivity C-reactive protein, an inflammatory surrogate marker. There is an ongoing phase-3 clinical trial, Ziltivekimab Versus Placebo Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease, and Systemic Inflammation trial (ZEUS), which will be essential for further anti-inflammation therapy for patients with CKD. Numerous clinical trials have investigated anti-inflammation therapies. Colchicine is by far the only one that has the potential to be widely used due to its cost-effectiveness. Further research is needed on other novel anti-inflammation therapies and their real-world implementation.

2024-06-01·Current opinion in lipidology

C-reactive protein, pharmacological treatments and diet: how to target your inflammatory burden

Review

作者: Bay, Benjamin ; Arnold, Natalie ; Waldeyer, Christoph

Purpose of review:

This article focuses on pharmacological agents as well as dietary changes aimed at the reduction of the inflammatory burden measured by circulating C-reactive protein concentrations.

Recent findings:

Over the last years, repurposed as well as new anti-inflammatory agents have been investigated in outcome trials in the cardiovascular field. Currently, a specific inhibition of the inflammatory cascade via the interleukin-6 ligand antibody ziltivekimab is being explored in large-scale outcome trials, after the efficacy of this agent with regard to the reduction of inflammatory biomarkers was proven recently. Next to the investigated pharmacological agents, specific dietary patterns possess the ability to improve the inflammatory burden. This enables patients themselves to unlock a potential health benefit ahead of the initiation of a specific medication targeting the inflammatory pathway.

Summary:

Both pharmacological agents as well as diet provide the opportunity to improve the inflammatory profile and thereby lower C-reactive protein concentrations. Whilst advances in the field of specific anti-inflammatory treatments have been made over the last years, their broad implementation is currently limited. Therefore, optimization of diet (and other lifestyle factors) could provide a cost effective and side-effect free intervention to target low-grade vascular inflammation.

2024-01-01·Journal of the American Society of Nephrology : JASN

Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3–5: An Analysis of a Randomized Trial (RESCUE)

Article

作者: Pergola, Pablo E ; Davidson, Michael ; Raj, Dominic S. ; Andreas Schytz, Philip ; Perkovic, Vlado ; Mohseni Zonoozi, Amir A ; Raj, Dominic S ; Jensen, Camilla ; Pergola, Pablo E. ; Mohseni Zonoozi, Amir A. ; Tuttle, Katherine R. ; Tuttle, Katherine R

Significance Statement:

Systemic inflammation in CKD can lead to anemia. Ziltivekimab, a fully human monoclonal antibody targeting the IL-6 ligand, has been shown to reduce systemic inflammation in patients with CKD. It has also been shown to increase serum albumin in patients on hemodialysis with inflammation and hyporesponsiveness to treatment with erythropoiesis-stimulating agents. This exploratory analysis of the RESCUE clinical trial found that among patients with CKD stage 3–5 and systemic inflammation, ziltivekimab treatment significantly increased hemoglobin (Hb) levels after 12 weeks compared with placebo. Ziltivekimab was also associated with significant increases in serum iron levels, total iron-binding capacity, and transferrin saturation. No major safety concerns were reported. Further clinical trials are warranted to study ziltivekimab's potential for anemia management in patients with CKD.

Background:

In the phase 2 RESCUE clinical trial, ziltivekimab, a fully human monoclonal antibody against the IL-6 ligand, significantly reduced the biomarkers of inflammation compared with placebo, in patients with CKD and systemic inflammation (high-sensitivity C-reactive protein ≥2 mg/L). The aim of this subanalysis of RESCUE trial data was to assess the effect of ziltivekimab on Hb and iron homeostasis in this patient population.

Methods:

This was an analysis of exploratory end points from the RESCUE trial (NCT03926117), which included 264 adults with CKD stage 3–5 and high-sensitivity C-reactive protein ≥2 mg/L. Participants received placebo or subcutaneous ziltivekimab (7.5, 15, or 30 mg) (1:1:1:1) once every 4 weeks, up to 24 weeks. End points for this analysis were changes in Hb and biomarkers of iron homeostasis from baseline to week 12.

Results:

The trial was terminated early due to the coronavirus disease 2019 pandemic, and thus, data up to week 12 are presented. Hb levels significantly increased from baseline to week 12 with ziltivekimab 7.5, 15, and 30 mg (treatment differences versus placebo: +0.57 g/dl [95% confidence interval, 0.27 to 0.86], +1.05 g/dl [0.76 to 1.33], and +0.99 g/dl [0.70 to 1.28], respectively, all P < 0.001). Ziltivekimab was associated with significant increases in serum iron levels, total iron-binding capacity, and transferrin saturation from baseline to week 12 (P < 0.05 versus placebo for all doses and comparisons). Cases of sustained thrombocytopenia, sustained neutropenia, anemia, and iron deficiency anemia were infrequent and similar across all groups.

Conclusions:

Anti-inflammatory therapy with ziltivekimab improved the markers of anemia and iron homeostasis in people with stage 3–5 CKD and systemic inflammation, suggesting a possible role in anemia management.

项与 Ziltivekimab 相关的新闻（医药）

2025-09-10

·生物制品圈

诺华 2025 并购提速：172 亿美金补管线

摘要：2025 年以来，瑞士制药巨头诺华的业务发展团队动作频频，在并购与授权交易上已投入 172.3 亿美元。其中，心血管领域成为重点布局方向，仅 9 月就达成三笔交易，包括以 14 亿美元收购 Tourmaline Bio。这一系列动作旨在应对多款核心药物即将失去专利保护的挑战，通过 “补强型交易” 充实管线，尤其是在心律失常等公司具有优势的治疗领域。九月三笔交易凸显并购力度进入 9 月，诺华的并购步伐明显加快。9 日，该公司宣布以 14 亿美元收购心血管生物科技公司 Tourmaline Bio，借此获得其针对动脉粥样硬化性心血管疾病（ASCVD）的 IL-6 靶向单克隆抗体 pacibekitug。据 BMO Capital Markets 分析，诺华为此支付了 37% 的溢价，凸显出该药物的潜力，它将与诺和诺德通过收购 Corvidia Therapeutics 获得的 III 期疗法 ziltivekimab 展开竞争。而在 9 月初，诺华还与 Argo Biopharmaceutical、Arrowhead Pharma 达成两项授权交易，总潜在价值达 75.6 亿美元。其中，与 Argo 的合作涉及多款针对心血管靶点的 siRNA 资产，交易总价值 53.6 亿美元，包括 1.6 亿美元预付款和 52 亿美元里程碑付款；与 Arrowhead Pharma 的交易则聚焦于针对突触核蛋白病的 siRNA 疗法 ARO-SNCA，总价值 22 亿美元，包含 2 亿美元预付款和 20 亿美元里程碑付款。巨额投入背后的管线焦虑诺华如此密集且大额的并购投入，与公司面临的专利悬崖压力密切相关。今年，其慢性心力衰竭药物 Entresto 将失去专利保护，此外，Xolair 今年也将遭遇仿制药竞争，Jakafi、Cosentyx 和 Tafinlar 等也将在 2030 年底前陆续失去专利 exclusivity。为应对这一局面，充实管线成为诺华的重要战略。在 7 月的二季度财报电话会议上，首席财务官 Harry Kirsch 就表示，公司正在寻求 “创造价值的补强型交易”。他还提到，由首席战略增长官 Ronny Gal 领导的业务发展团队在过去两年已签署 30 笔交易，今年 4 月与 Regulus Therapeutics 达成的 17 亿美元交易便是典型案例，该交易为诺华的寡核苷酸产品线增添了常染色体显性多囊肾病（ADPKD）疗法 farabursen。聚焦优势领域，剑指大市场在布局方向上，诺华将目光投向了自身具有独特优势的领域。公司高管曾在 2024 年底表示，希望到 2025 年底在心律失常领域拥有多个临床阶段资产，首席执行官 Vas Narasimhan 在财报电话会议上重申了这一目标的重要性。为此，诺华已签署多项临床前资产的授权交易，包括 6 月与 Flagship Pioneering 旗下 ProFound Therapeutics 的合作。“心律失常领域是我们拥有独特专长的领域，可能也是少数仍在致力于解决心脏节律问题的公司之一。”Narasimhan 向分析师表示，“显然，若能成功，这里的市场规模相当大，对于患者而言，药物治疗相较于基于设备的心脏复律具有显著吸引力。” 从目前的交易来看，心血管领域已成为诺华 2025 年的布局重点，年内已达成四笔相关交易。业内人士认为，随着并购的持续推进，诺华有望在应对专利悬崖的同时，为未来的增长奠定基础。参考来源：https://www.biospace.com/business/novartis-busy-bd-team-keeps-2025-bolt-on-deal-promises 识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

2025-09-09

·医药经济报

14亿美元收购辉瑞“弃子”，诺华图什么？

药物研发领域的“资产流转”再添新的经典案例。 9月9日，诺华宣布已与临床阶段的生物制药公司Tourmaline Bio达成一项收购协议，将以每股48美元的价格收购后者，总交易额约为14亿美元，预计在2025年第四季度完成。据悉，Tourmaline Bio唯一的核心资产Pacibekitug（TOUR006）是一款临床在研长效抗IL-6单抗，正在开发作为动脉粥样硬化性心血管疾病（ASCVD）的新治疗选择。炎症是心血管疾病的主要驱动因素，但目前尚无广泛采用的抗炎疗法可用于降低心血管风险。而TOUR006靶向的IL-6是一种促进全身炎症的关键上游细胞因子，将解决未被满足的临床需求。诺华认为，TOUR006的Ⅱ期临床进展顺利，通过并购获得该Ⅲ期临床就绪资产，将补充其现有的心血管疾病产品组合。值得一提的是，TOUR006最早由辉瑞研发（研发代号PF-04236921），后被视为超出需要的多余项目资产，被出售给Tourmaline Bio。然而，与辉瑞的研发思路相异，Tourmaline Bio使TOUR006走上了治疗炎症疾病的不同路径，最终被诺华收购。强化心血管核心战略 Tourmaline Bio成立于2021年，其创始人兼CEO Sandeep Kulkarni曾任投资机构KVP Capital的董事总经理，亦曾担任Immunovant、Roivant等多家纳斯达克上市企业高管。2023年6月，Tourmaline Bio宣布与老牌细胞疗法上市公司Talaris Therapeutics达成合并协议，借壳登陆纳斯达克。 Tourmaline Bio目前唯一的管线便是诺华这次收购的核心目标TOUR006。TOUR006和BMS的O药皆由Medarex的转基因小鼠平台生成，最早由辉瑞进行开发，彼时的研发代号为PF-04236921。2010—2016年，辉瑞在克罗恩病、红斑狼疮和类风湿性关节炎患者中开展TOUR006的早期临床试验，这一开发重心与赛诺菲/再生元、罗氏等其他IL-6靶向药物开发商基本重合。但罗氏的托珠单抗、赛诺菲/再生元的Sarilumab分别在2010年、2017年相继获得FDA批准，彼时尚处于早期临床的TOUR006并不具备明显的竞争优势，以至于被辉瑞一度视为超出需要的多余项目资产。2022年5月，瞄准机会的Tourmaline Bio与辉瑞达成协议，获得TOUR006的全球独家开发和商业化权利。 Tourmaline Bio认为，在炎症疾病和自免疾病中，IL-6通路抑制剂展现出令人信服的临床获益信号，但尚未得到充分开发。于是，Tourmaline Bio为TOUR006制定了多个方面的临床开发计划，包括动脉粥样硬化性心血管疾病（ASCVD）、甲状腺眼病（TED）以及腹主动脉瘤（AAA）。今年5月，Tourmaline Bio公布了TOUR006的Ⅱ期临床TRANQUILITY研究首批结果。该试验评估了高敏C反应蛋白（hs-crp）升高的患者每季度和每月皮下注射TOUR006，与心血管风险升高和慢性肾脏疾病（CKD）相关的生物标志物。结果显示，最高剂量的TOUR006在90天内使患者的炎症指标高敏C反应蛋白（hs-CRP）水平降低了86%，而接受安慰剂治疗的受试者的hs-CRP水平仅降低了15%。该研究结果证明，TOUR006可大幅减少通常与心脏病相关的炎症程度，支持其在ASCVD和其他心血管疾病患者中开展后期试验。押宝TOUR006的背后，是诺华对其心血管疾病管线战略布局的深思熟虑。心血管－肾脏－代谢管线对诺华的贡献仅次于肿瘤学，今年上半年为诺华创造了51.73亿美元收入，同比增长26%。其中，兼具降压和抗心力衰竭作用的重磅药物沙库巴曲缬沙坦（诺欣妥）仍是诺华的支柱产品，46.18亿美元销售额和同比22%的强劲增长令其继续霸榜诺华全球最畅销产品。但诺欣妥正在迎来更多竞争对手。尽管诺欣妥在第十一批国采中因存在专利侵权高风险而被豁免纳入，但已有南京一心和、科伦药业两家国内企业的同品种药物突破专利壁垒上市。不仅如此，诺欣妥在美国市场的独占期也正在受到来自MSN制药、瑞迪博士等公司的多款仿制药挑战。这笔收购是在诺华强化心血管核心治疗领域的战略背景下诞生的，其看中了TOUR006这款药物在解决心血管残余炎症风险这一巨大未满足医疗需求方面的独特价值。这是一个典型的“引进创新”策略，通过收购具有高度协同性和市场前景的晚期资产，来快速巩固和扩展自己在关键领域的领导地位。同时，Tourmaline Bio也在探索TOUR006用于TED等其他适应症。诺华收购Tourmaline Bio后，可能也会评估这些机会，进一步挖掘该药物的价值。疗效仍需明确证实在全球慢性病发病率持续攀升的背景下，心血管系统用药作为预防和治疗心脏及血管相关疾病的关键药物类别，市场需求保持稳定增长。根据QYResearch调研数据，2024年全球心血管系统用药销售额已达988亿美元，预计2031年将增长至1298亿美元，展现出该领域的持续发展潜力。截至目前，全球已有多款靶向IL-6或IL-6R的药物获批上市，包括罗氏的托珠单抗、赛诺菲/再生元的Sarilumab、强生的司妥昔单抗和罗氏/Chugai的萨特利珠单抗等，但仍未有产品拿下治疗心血管疾病的适应症。除了这次被诺华收购的TOUR006，诺和诺德的Ziltivekimab同样值得关注。 Ziltivekimab最初是由Corvidia Therapeutics研发的IL-6单抗药物，旨在通过抑制IL6降低全身炎症。凭借延长半衰期的技术，Ziltivekimab为每月皮下注射一次。2020年6月，诺和诺德宣布收购Corvidia Therapeutics，将Ziltivekimab收入囊中。根据协议，诺和诺德将支付给Corvidia Therapeutics7.25亿美元前期付款，总交易额最高可达到21亿美元。 Ⅱ期研究数据显示，与安慰剂相比，Ziltivekimab可使hs-CRP水平降低约90%。目前，Ziltivekimab在研适应症为ASCVD伴CKD、急性心肌梗死（AMI）和心力衰竭（HFpEF），相关试验均已推进至Ⅲ期临床。不仅如此，CSL Behring申报的clazakizumab也在2024年于国内获批临床，拟开发用于降低接受维持性透析的成人患者的心血管死亡和心肌梗死风险，这些患者具有系统性炎症证据并且患有动脉粥样硬化性心血管疾病或糖尿病。公开资料显示，clazakizumab是一种靶向IL-6配体的单抗，其治疗慢性活动性抗体介导的排斥反应（AMR）的适应症开发在国际范围内处于Ⅲ期临床阶段。抗IL-6单抗在心血管疾病领域的研发特别是针对ASCVD，是当前的热门方向。这背后的核心思路为：炎症是心血管疾病的一个重要独立风险因素，仅仅控制胆固醇等传统因素可能还不够。虽然前景可观，但抗IL-6单抗在心血管领域的开发也面临多个关键挑战，例如疗效还需明确证实，Ⅱ期研究主要观察的是hs-CRP等生物标志物的改善。然而，药品监管机构批准药物用于心血管领域，通常需要大规模Ⅲ期研究证实，其能显著降低主要不良心血管事件（MACE），如心脏病发作、卒中或心血管死亡的发生率，这是抗IL-6药物需要最终跨越的“金标准”。此外，IL-6通路在免疫防御中也有作用，长期抑制IL-6可能需要密切关注感染风险，如严重感染、机会性感染等，以及对血脂水平和肝功能的潜在影响。目前，相关在研的Ⅱ期数据表明安全性尚可，但大规模长期试验的数据至关重要。尽管诺和诺德的Ziltivekimab和诺华刚刚收购的TOUR006处于领先地位，但Ⅲ期临床的结果才是真正的“试金石”。未来几年，随着这些大型临床试验数据的读出，业界将更清楚地了解这类药物在心血管疾病防控中的确切价值。如果成功，这不仅是新药的诞生，更意味着心血管疾病治疗理念的一次重要演进。编辑：范晓艳版式编辑：于成林审校：马飞、张松创新药“狂飙”与CXO“转型”，BD潮涌下的产业变局与新机第十一批国采允许复活，报价跟进最高有效申报价 1.55亿底价转让！"国药系"连续7次出手，边买边卖意欲何为？ www.yyjjb.com.cn 洞悉行业趋势长按关注医药经济报《中国处方药》学术公众号聚焦药学学术和循证研究长按关注中国处方药《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店

并购临床2期细胞疗法

2025-09-09

·EndPoints

Novartis to spend $1.4B on Tourmaline Bio, gaining new heart drug

Novartis said Tuesday that it would buy Tourmaline Bio for $1.4 billion in a bid to revitalize its cardiovascular offering. The Swiss pharma said it would pay $48 per share in cash for Tourmaline, a premium of nearly 60% to the biotech’s closing price on Monday. Tourmaline’s main asset, an anti-IL-6 antibody called pacibekitug, generated promising mid-stage data in atherosclerotic cardiovascular disease in May. And Novartis is looking to revitalize its heart disease drug pipeline, considering the patent for its heart failure blockbuster Entresto is set to expire soon. Entresto is Novartis’ bestselling drug, making over $4 billion last year. In Tourmaline’s trial, called TRANQUILITY, pacibekitug sharply cut levels of an inflammation marker called high-sensitivity C-reactive protein (hs-CRP) in patients with chronic kidney disease. Both the disease and the biomarker are risk factors for atherosclerosis, a condition in which plaque builds up in the arteries, raising the risk of events like heart attacks and strokes. A further cut from the study, presented at the annual meeting of the European Society of Cardiology last month, showed that the reductions in hs-CRP were consistent across subgroups, and the drug also cut levels of other disease biomarkers, including lipoprotein(a), fibrinogen and serum amyloid A. Analysts from Leerink wrote in a Sept. 2 note that the TRANQUILITY results “showcase pacibekitug’s competitive balance of efficacy and safety,” adding that the drug’s less frequent subcutaneous dosing could be a differentiator versus other drugs. Tourmaline’s antibody may be dosed quarterly, whereas competing IL-6 products like CSL Behring’s Phase 3-stage clazakizumab and Novo Nordisk’s ziltivekimab are given monthly. Ziltivekimab is in a late-stage trial called ZEUS in patients with cardiovascular disease, chronic kidney disease and inflammation, which is due to yield data next year. Success on a surrogate biomarker endpoint is a start, but pacibekitug will have to prove itself in a larger Phase 3 investigation to see if it really does reduce the risk of heart events. Tourmaline was known to be planning a cardiovascular outcomes trial of the drug in ASCVD. Pacibekitug is designed to reduce systemic inflammation by blocking IL-6. Novartis said that inflammation is a major driver of cardiovascular disease. The antibody, which came from Pfizer, is also being tested in thyroid eye disease , with a Phase 2 trial set to report in 2026. And Tourmaline was also planning to start a proof-of-concept study in a second vascular indication called abdominal aortic aneurysm this year. Novartis will buy Tourmaline through an indirect wholly-owned subsidiary called Torino Merger Sub. After the tender offer is completed, Novartis intends to merge the acquiring subsidiary with Tourmaline, resulting in the latter becoming a Novartis subsidiary.

临床3期并购AHA会议临床结果

100 项与 Ziltivekimab 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性心肌梗塞	临床3期	美国	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	中国	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	日本	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	阿根廷	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	澳大利亚	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	巴西	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	保加利亚	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	加拿大	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	捷克	Novo Nordisk A/S	2024-06-25
急性心肌梗塞	临床3期	丹麦	Novo Nordisk A/S	2024-06-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03926117 (RESCUE, Pubmed) 人工标引	临床2期	炎症 \| 慢性肾病 C-reactive Protein Expression	261	Ziltivekimab 7.5 mg	壓夢襯壓顧齋鹹鹽遞簾(願獵願醖衊構窪獵齋齋) = 簾膚選遞壓蓋鏇鏇衊構淵鑰範選醖觸夢壓範鹹 (範蓋觸襯襯製遞憲構廠 )	积极	2024-01-01
				Ziltivekimab 15 mg	壓夢襯壓顧齋鹹鹽遞簾(願獵願醖衊構窪獵齋齋) = 醖積製壓夢遞網鏇願齋淵鑰範選醖觸夢壓範鹹 (範蓋觸襯襯製遞憲構廠 )
NCT04626505 (RESCUE-2, Pubmed \| J Cardiol)	临床2期	动脉粥样硬化 high-sensitivity C-reactive protein (hsCRP)	-	Ziltivekimab 15mg	鹽遞膚鏇積鑰憲製艱蓋(鑰顧夢遞餘簾繭選鏇獵) = 餘獵襯願鬱廠醖鏇艱蓋網糧鑰夢積醖廠選觸遞 (淵製範糧簾繭選製鏇顧 )	积极	2023-10-01
				Ziltivekimab 30mg	鹽遞膚鏇積鑰憲製艱蓋(鑰顧夢遞餘簾繭選鏇獵) = 網夢築糧製遞壓鹽鏇蓋網糧鑰夢積醖廠選觸遞 (淵製範糧簾繭選製鏇顧 )
NCT03926117 (RESCUE \| RESCUE Trial, CTgov)	临床2期	炎症 \| 慢性肾病	264	Ziltivekimab (Placebo)	簾觸鑰鏇糧構鬱齋範醖(範餘鹽夢膚製鹹醖糧願) = 範廠艱獵窪夢選築鹽艱鬱繭鹽選鑰窪網淵壓齋 (繭鏇願鏇憲積鹽襯願窪, 範鹽糧繭選膚繭壓艱蓋 ~ 鹹選夢艱夢壓廠衊遞願) 更多	-	2023-08-09
				Ziltivekimab (Ziltivekimab 7.5 mg)	簾觸鑰鏇糧構鬱齋範醖(範餘鹽夢膚製鹹醖糧願) = 餘遞淵夢膚窪淵餘衊憲鬱繭鹽選鑰窪網淵壓齋 (繭鏇願鏇憲積鹽襯願窪, 鹽鏇壓蓋鏇願遞襯鏇選 ~ 壓簾糧觸齋遞醖顧糧鬱) 更多
NCT03926117 (RESCUE Trial, ASN2021)	临床2期	慢性肾病 serum hemoglobin \| iron homeostasis \| high-sensitivity C-reactive protein	-	Ziltivekimab 7.5 mg	膚鏇淵獵壓廠網鹽艱願(顧壓艱範鹽齋顧願鑰鏇) = 積遞衊夢構顧遞鏇壓遞醖淵淵積鏇範廠廠壓製 (繭廠糧壓繭製築範鏇醖 )	积极	2021-10-27
				Ziltivekimab 15 mg	膚鏇淵獵壓廠網鹽艱願(顧壓艱範鹽齋顧願鑰鏇) = 範鏇製獵餘構鏇顧蓋襯醖淵淵積鏇範廠廠壓製 (繭廠糧壓繭製築範鏇醖 )
NCT02868229 (CTgov)	临床1/2期	贫血	61	Placebo (Placebo)	鏇獵廠顧壓憲築淵鑰糧 = 壓繭範製繭膚顧範願憲鑰餘獵觸願獵夢窪鹽鏇 (鏇獵艱廠製餘製獵夢選, 鑰範壓膚蓋鏇襯範網鬱 ~ 餘鹹繭獵鏇範衊築淵範) 更多	-	2021-07-30
				COR-001 (COR-001)	襯鑰範淵衊鹽製淵遞窪(窪築願積繭憲蓋範構鑰) = 襯選壓夢衊鏇襯觸淵蓋窪壓鹽製選壓願壓鏇積 (構淵鏇築襯築窪蓋衊廠, 膚窪壓醖淵網憲衊夢構 ~ 鹹築觸網膚製願築鏇衊)
NCT03926117 (RESCUE, Pubmed \| Lancet)	临床2期	动脉粥样硬化	264	Placebo	醖齋鹽鏇觸鏇獵範糧觸(繭觸網艱遞糧構鏇廠夢) = 膚顧鹹獵膚襯鑰糧築鏇齋繭淵網願糧繭積醖鏇 (積廠淵顧構鹹壓構蓋鹹 )	积极	2021-05-14
ASN2019	临床1期	慢性肾病	12	COR-001 5 mg	艱壓選網願淵艱窪艱選(觸鹹衊廠觸鑰鹹壓願積) = 淵艱網憲鹹獵鏇鑰範構繭壓鏇衊簾餘鬱廠餘蓋 (顧窪構範鹽窪淵選積糧 )	积极	2019-11-05
				COR-001 15 mg	艱壓選網願淵艱窪艱選(觸鹹衊廠觸鑰鹹壓願積) = 襯鬱蓋壓範衊壓範艱蓋繭壓鏇衊簾餘鬱廠餘蓋 (顧窪構範鹽窪淵選積糧 )